PRESS Intervention for Pyemia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Washington University, Saint Louis, MO
Pyemia+1 More
PRESS Intervention - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if an emergency medical services (EMS) based sepsis screening and early warning protocol can improve the timing of sepsis care in the emergency department (ED). PRESS Intervention is being used to treat Pyemia in this trial, and patients will not be receiving a placebo. PRESS Intervention has been approved by the FDA for a different condition in the past.

Eligible Conditions

  • Pyemia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Pyemia

Study Objectives

1 Primary · 9 Secondary · Reporting Duration: During hospital stay (up to 20 days, on average)

Day 1
EMS Documentation of Sepsis
EMS Documentation of a Prehospital Sepsis Alert
Proportion of Patients Without Sepsis Receiving Antibiotics in the ED
Time to First Antibiotic Administration in the ED
Time to First Care Provider Documentation
Time to Sepsis Bundle from ED Arrival
Day 20
Hospital Length of Stay
In-hospital Death
Proportion of Patients Admitted to the ICU
Day 10
Antibiotic Days of Therapy

Trial Safety

Safety Progress

1 of 3

Other trials for Pyemia

Trial Design

2 Treatment Groups

Standard of Care
1 of 2
PRESS Intervention
1 of 2
Active Control
Experimental Treatment

1000 Total Participants · 2 Treatment Groups

Primary Treatment: PRESS Intervention · No Placebo Group · N/A

PRESS Intervention
Behavioral
Experimental Group · 1 Intervention: PRESS Intervention · Intervention Types: Behavioral
Standard of CareNoIntervention Group · 1 Intervention: Standard of Care · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: during hospital stay (up to 20 days, on average)
Closest Location: Washington University · Saint Louis, MO
Photo of university of washington 1Photo of university of washington 2Photo of university of washington 3
2008First Recorded Clinical Trial
0 TrialsResearching Pyemia
517 CompletedClinical Trials

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,498 Previous Clinical Trials
2,665,327 Total Patients Enrolled
Centers for Disease Control and PreventionFED
819 Previous Clinical Trials
21,536,816 Total Patients Enrolled
Jonathan E Sevransky, MD, MHSPrincipal InvestigatorEmory University
1 Previous Clinical Trials
70 Total Patients Enrolled
Carmen C Polito, MD, MScPrincipal InvestigatorEmory University

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a systolic blood pressure of less than 110 mmHg.
You must be 40 years of age or older.
You have a minimum oxygen saturation of at least 90%.
You are a nursing home patient.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.